Please wait a minute...
Journal of ZheJiang University(Medical Science)  2016, Vol. 45 Issue (1): 81-85    DOI: 10.3785/j.issn.1008-9292.2016.01.13
Platelet count predicts therapeutic response of infliximab for active Crohn's disease
SHEN Haiyan1,2, XU Chengfu1, CHEN Chunxiao1
1. Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;
2. Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine, Jiaxing College, Jiaxing 314000, China
Download:   PDF(826KB)
Export: BibTeX | EndNote (RIS)      


Objective: To explore the platelet count in prediction of the efficacy of infliximab for active Crohn's disease. Methods: A total of 74 patients with Crohn's disease, including 50 males and 24 females with mean age of 27 years, receiving infliximab therapy from January 2011 to June 2015 were retrospectively included. Clinical variables including routine blood test, erythrocyte sedimentation rate, C-reactive protein and Crohn's disease activity index were measured before treatment and after 3rd, 6th treatments. Results: Compared with baseline, the Crohn's disease activity index score, white blood cell count, platelet count, erythrocyte sedimentation rate, C-reactive protein significantly decreased (all P<0.01), while hemoglobin and red blood cell hematocrit increased (P<0.01) in patients after 3 treatments of infliximab. These variables were further improved after 6 treatments. Further analysis showed that platelet count was positively associated with disease severity of Crohn's disease. Fifty-three patients achieved clinical remission (Crohn's disease activity index score < 150) after 3 treatments of infliximab. Logistic regression analysis showed that baseline platelet count, Crohn's disease activity index, and disease course were three predictors for clinical remission of Crohn's disease. Conclusion: Platelet count is positively associated with disease severity of Crohn's disease, and baseline platelet count is an important predicator for the early response of infliximab therapy.

Key wordsCrohn disease/therapy      Antibodies, monoclonal/therapeutic use      Platelet count      Treatment outcome      Forecasting     
Received: 15 October 2015     
CLC:  R574.62  
Cite this article:

SHEN Haiyan, XU Chengfu, CHEN Chunxiao. Platelet count predicts therapeutic response of infliximab for active Crohn's disease. Journal of ZheJiang University(Medical Science), 2016, 45(1): 81-85.

URL:     OR



关键词: Crohn病/治疗,  抗体,单克隆/治疗应用,  血小板计数,  治疗结果,  预测 
[[1]]   SINGH N, ROSENTHAL C J, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2014, 20(10):1708-1713.
[[2]]   SATO S, CHIBA T, NAKAMURA S, et al. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis[J]. J Gastroenterol Hepatol, 2015, 30(10):1467-1472.
[[3]]   JVRGENS M, MAHACHIE JOHN J M, CLEYNEN I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease[J]. Clin Gastroenterol Hepatol, 2011, 9(5):421-427.e1.
[[4]]   中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2012年)[J].中华内科杂志, 2012, 51(10):818-831. Digestive Disease Branch of Inflammatory Bowel Disease Study Group of the Chinese Medical Association. The diagnosis and treatment of inflammatory bowel disease consensus (2012)[J]. Chinese Journal of Internal Medicine, 2012, 51(10):818-831. (in Chinese)
[[5]]   REINISCH W, SANDBORN W J, RUTGEERTS P, et al. Long-term infliximab maintenance therapy for ulcerative colitis:the ACT-1 and-2 extension studies[J]. Inflamm Bowel Dis, 2012, 18(2):201-211.
[[6]]   SANDBORN W J, ABREU M T, D'HAENS G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab[J]. Clin Gastroenterol Hepatol, 2010, 8(8):688-695.e2.
[[7]]   LICHTENSTEIN G R, ABREU M T, COHEN R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease[J]. Gastroenterology, 2006, 130(3):940-987.
[[8]]   TRAVIS S, VAN ASSCHE G, DIGNASS A, et al. On the second ECCO Consensus on Crohn's disease[J]. J Crohns Colitis, 2010, 4(1):1-6.
[[9]]   D'HAENS G R, PANACCIONE R, HIGGINS P D, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization:when to start, when to stop, which drug to choose, and how to predict response?[J]. Am J Gastroenterol, 2011, 106(2):199-212.
[[10]]   ORLANDO A, ARMUZZI A, PAPI C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines:the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease[J]. Dig Liver Dis, 2011, 43(1):1-20.
[[11]]   SCHNITZLER F, FIDDER H, FERRANTE M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease:results from a single-centre cohort[J]. Gut, 2009, 58(4):492-500.
[[12]]   LÖNNKVIST M H, THEODORSSON E, HOLST M, et al. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy[J]. Scand J Gastroenterol, 2011, 46(4):420-427.
[[13]]   石云华, 何松. 英夫利昔与硫唑嘌呤联用与单药治疗炎症性肠病的Meta分析[J]. 世界华人消化杂志, 2015,23(12):2003-2010. SHI Yunhua, HE Song. Inflixmab and azathioprine combination therapy vs monotherapy for inflammatory bowel disease:a meta-analysis[J]. World Chinese Journal of Digestology, 2015, 23(12):2003-2010. (in Chinese)
[[14]]   ÖZTVRK Z A, DAG M S, KUYUMCU M E, et al. Could platelet indices be new biomarkers for inflammatory bowel diseases?[J]. Eur Rev Med Pharmacol Sci, 2013, 17(3):334-341.
[[15]]   LIU S, REN J, HAN G, et al. Mean platelet volume:a controversial marker of disease activity in Crohn's disease[J]. Eur J Med Res, 2012, 17:27.
[1] CHEN Gang,ZHANG Ding,YING Yacao,WANG Zhifeng,TAO Wei,ZHU Hao,ZHANG Jingfeng,PENG Zhiyi. Clinical investigation on transarterial chemoembolization with indigenous drug-eluting beads in treatment of unresectable hepatocellular carcinoma[J]. Journal of ZheJiang University(Medical Science), 2017, 46(1): 44-51.
[2] XIA Guangfa, ZHU Juanying, YUAN Jun, CAO Bo, TANG Jie, CHEN Yiding. Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy[J]. Journal of ZheJiang University(Medical Science), 2016, 45(6): 614-619.
[3] LI Wenbo, DING Gaoheng, LIU Jun, SHI Jie, ZHANG Chao, GAO Qiuming. Operative versus non-operative treatment for three- or four-part proximal humeral fractures in elderly patients: a meta-analysis of randomized controlled trials[J]. Journal of ZheJiang University(Medical Science), 2016, 45(6): 641-647.
[4] HE Bin, CHAI Yanlan, WANG Tao, ZHOU Zhenxing, LIU Zi. Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer[J]. Journal of ZheJiang University(Medical Science), 2016, 45(4): 395-402.
[5] LU Han-ti, LI Fu-dong, LIN Jun-fen, HE Fan, SHEN Yi. Construction of early warning model of influenza-like illness in Zhejiang Province based on support vector machine[J]. Journal of ZheJiang University(Medical Science), 2015, 44(6): 653-658.
[6] ZHAI Li-ping, CHEN Zhi-cai, YAN Shen-qiang, ZHONG Gen-long, ZHANG Sheng, XU Meng-jun, LOU Min. Older age is not related to hemorrhagic transformation and favorable outcomes in patients with wake-up ischemic stroke undergoing intravenous thrombolytic therapy[J]. Journal of ZheJiang University(Medical Science), 2015, 44(6): 638-644.
[7] HUANG Xue-cai, YANG Ling-ling. Comparison clinical efficacy of 3% hypertonic saline solution with 20% mannitol in treatment of intracranial hypertension in patients with aneurysmal subarachnoid hemorrhage[J]. Journal of ZheJiang University(Medical Science), 2015, 44(4): 389-395.
[8] HE Ling-fei, ZHAO Yun, WANG Zheng-ping. Prediction model of fetal meconium-stained amniotic fluid in re-pregnant women with intrahepatic cholestasis of pregnancy[J]. Journal of ZheJiang University(Medical Science), 2015, 44(3): 264-268.
[9] ZHU Chang-kun, WANG Fei, ZHOU Yu-mei, YING Jun, CHEN Dan-qing. Maternal outcomes in pregnant women with pernicious placenta previa[J]. Journal of ZheJiang University(Medical Science), 2015, 44(3): 253-257.
[10] JIANG Jin-hong, XU Wei-lai, QIAN Wen-bin. Imatinib mesylate for chronic myeloid leukemia:in patients with initial treatment versus those with Recombinant Human IFN-α2b treatment failure[J]. Journal of ZheJiang University(Medical Science), 2015, 44(2): 179-183.
[11] YUAN Wei-an, SHEN Zhi-bi, XUE Li, TAN Wen-li, CHENG Ying-wu, ZHAN Song-hua, ZHAN Hong-sheng. Effect of spinal manipulation on brain functional activity in patients with lumbar disc herniation[J]. Journal of ZheJiang University(Medical Science), 2015, 44(2): 124-130,137.
[12] LV Jie-min, Huang Di-yu, Lin Hui, Wang Xian-fa. Laparoscopic anti-reflux surgery with biological mesh in treatment of gastroesophageal reflux disease[J]. Journal of ZheJiang University(Medical Science), 2015, 44(1): 74-78,84.
[13] LU Zhou, QIU Xiao-dong, REN Ya-chun, et al.. Treatment of distal clavicle type Ⅱ fracture: suture anchor versus clavicular hook plate[J]. Journal of ZheJiang University(Medical Science), 2014, 43(5): 577-.
[14] WENG Xiu-Mei, PAN Jian-Ping. Bone alkaline phosphatase and N-MID osteocalcin in monitoring of osteoporosis treatment with recombinant human parathyroid hormone 1-34[J]. Journal of ZheJiang University(Medical Science), 2013, 42(5): 578-582.
[15] YU Zhong, XIANG Mei-Xiang, MA Chang-Sheng, ZHANG Shu-Long, YANG Yan-Zong. Efficacy and safety of ibutilide for conversion of atrial fibrillation/flutter[J]. Journal of ZheJiang University(Medical Science), 2013, 42(2): 212-216.